$PVSP a developer of companies and technologies in high

New Post Public Reply Private Reply Replies (0) Message Board
budfoxfun
180
$PVSP a developer of companies and technologies in high value emerging markets, together with Zen Asset Management today announced its 2-year strategic roadmap.

“On the heels of Artizen Corporation’s reverse merger to acquire Pervasip Corp, the cannabis industry experienced a dramatic post pandemic contraction. Planned restructuring efforts had already launched in late 2021 and we took even more aggressive steps to further rationalize our business, dispose of undervalued assets, re-focus on higher margin products and allowed our leading brands to take a more aggressive posture to increase market share. Healthy inventory amounts provided for extraordinary financing via cashflow, albeit at extremely low margins, a carefully considered short term decision which has now come to an end as we have achieved our goals. All these efforts position us nicely for healthy financial growth in 2023. As promised, we have also finalized a 24-month roadmap and are in a position to provide carefully considered guidance in a market that is still extremely unpredictable,” said German Burtscher, Pervasip CEO. “It is also important to note that all the Artizen brands’ revenue is wholesale, revenue derived from sales to retailers. The vast majority of MSOs report revenues and resulting financials that include retail sales from stores they own in addition to usually rather small wholesale revenue, all mostly generated in protected markets. Washington State (WA) cannabis sales are taxed at 47% (!) and each dollar sold by a producer/processor is marked up 3 – 3.5 times by the retailers they sell to. Generating profitable revenue in WA will translate extremely well once our brands and operating expertise is applied in other recreational markets.”

Market Overview – Washington

The below Washington State (WA) sales by category chart provides information on how monthly sales of approximately $100 million in retail sales breaks down by product category. It might also be informative to understand that June ’22 sales over June ’19 sales (pre pandemic) show an almost 17% increase. While WA sales are slightly above other mature cannabis states (NV, CO, OR), similar increases can be seen in those markets. An exuberant pandemic triggered belief in continued rapid growth has led to over development of production infrastructure and resulted in material oversupply of bulk cannabis flower. The market is in the process of correcting and the Company estimates Q3 2023 being the end of the corrective period, resulting in strengthening prices.


$100M In Monthly Sales By Category



After several years of recreational sales, the mature markets provide relevant insights into future sales distribution across key categories with flower and pre-rolls still leading at 59%, followed by concentrates (dabs/vape) at 29% and finally edibles and beverages at a combined 9%
Artizen brands will materially expand their flower market share and enter the concentrates and edibles market with a goal of occupying top 10% market share positions in each vertical.

Strategic Outlook Summary through Q4 2024

Focus on expanding its Washington State footprint, strengthening its brand repertoire and aggressively expanding its product lineup

We expect in-state revenues generated by all brands and across all product categories to reach $30 million in annualized revenue by end of Q4 2024 with Gross Margins reaching 40% and an adjusted EBIDTA of 30%

Pervasip/Artizen Corp plans to expand its national reach by adding various recreational states to its brand footprint, either via licensing agreements or through acquisitions of recreational cultivation and retail licenses

95% of revenue from Artizen’s brands has come from sales of cannabis flower, supporting its position of the 9th most sold independent flower brand in North America; acquisitions and partnerships will open access to concentrates and edible verticals representing 40% of market sales and heretofore not covered by Artizen products

Artizen projects it will generate $50 million in annualized revenues nationally by end of Q4 2024; this is a conservative estimate that does not include any potential revenue multiples from acquisition of retail opportunities.


24 Months plan detail

Rename Pervasip Corp to Artizen Corporation by year end 2022 to better reflect the new focus of the company

Change the OTC ticker symbol

Re-brand all Pervasip/Artizen assets

Continue to rationalize the business through Q1 2023 with a focus on operating margins, shedding underperforming assets, consolidating operations and focus in-house talent on higher margin operations and product lines

Acquire concentrates assets by end of 2022, launching into the highly lucrative concentrates business

Expand flower and concentrates offerings within our brands as well as adding new brands for certain product offerings and price points through Q1 2023

Complete the audit and begin the OTC QB application process during Q2 2023

Launch Artizen Wellness Q2 2023

Enter the edibles market in Q2 2023 via acquisition and partnerships

Artizen becomes an MSO with cultivation and retail assets in 1 – 2 additional states during 2nd half of 2024, beginning its state expansion in Q1 2023, initially through brand licensing opportunities and strategic partnerships, and eventually via acquisitions and mergers during Q3 and Q4 2024

Close first brand licensing agreement by end of Q4 2022

Close one brand licensing deal every quarter thereafter

Financial Outlook Q3 2022 through Q4 2023

Reach $2.0 million in monthly revenue by end of Q1 2023

Reach $2.5 million or $30 million in annualized revenue by end of Q4 2023 with 30% in adjusted EBIDTA

Reach $3.0 million or $36 million in annualized revenues by end of Q2 2024 with 35% in adjusted EBIDTA

Reach $50 million in annualized revenue with 35% in adjusted EBIDTA
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 118

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 180

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 17

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 71

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 88

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading

Top 5 Most Recently Viewed Articles

Canada Nickel Secures EDC Interest for $500 Million Financing

Updated Category News Views 137

Canada Nickel's Significant Financing Achievement Canada Nickel Company Inc. is excited to share a major milestone in its efforts to secure financing for the Crawford Nickel Sulphide Project. The company has received a Letter of Interest (LOI) from Export Development Canada (EDC), indicating its intention to offer up to US$500 million in long-term debt financing for the...

Continue Reading
BlackRock Expands Offerings with New ETF Share Class Approval

Updated Category News Views 202

BlackRock Pursues SEC Approval for ETF Share Classes BlackRock Inc (NYSE: BLK) is making headlines as it has formally applied to the U.S. Securities and Exchange Commission (SEC) for a ruling that would allow the establishment of exchange-traded fund (ETF) share classes linked to its existing mutual funds. This significant move positions BlackRock as the largest firm...

Continue Reading
Profusa Unveils Innovative AI Portal for Continuous Biochemistry Monitoring

Updated Category News Views 133

Profusa Introduces AI-Powered Insight Portal for Biomarker Monitoring Profusa, a pioneering company in digital health technology, is transforming how healthcare providers monitor patient biochemistry through an innovative AI-driven insight portal. This advanced portal will enhance continuous biomarker tracking, utilizing cutting-edge technology to provide clinical...

Continue Reading
Investigation Launch for Pliant Therapeutics Investors: What to Know

Updated Category News Views 192

Investigation of Pliant Therapeutics, Inc. Pliant Therapeutics, Inc. (NASDAQ: PLRX) is currently under scrutiny as investors seek clarity on potential securities law violations. This investigation presents an opportunity for shareholders who believe they have been misled regarding their investments. Shareholders are encouraged to come forward to ensure their rights are...

Continue Reading
Fish Window Cleaning's New Headquarters: A Step Forward in Growth

Updated Category News Views 2161

Fish Window Cleaning Unveils New Corporate Headquarters Fish Window Cleaning Services is excited to announce the grand opening of its brand-new corporate headquarters, a facility that signifies an important milestone in its growth and operational capabilities. Located at 217 Chesterfield Towne Centre, this expansive 12,500-square-foot space is intended to serve as the...

Continue Reading